Beijing Tiantan Biological Products' (SHA:600161) unit, Chengdu Rongsheng Pharmaceutical, plans to officially start the phase III clinical trials for its human coagulation factor IX, according to a Shanghai Stock Exchange disclosure on Tuesday.
The drug will be tested as a treatment of bleeding in patients with factor IX deficiency or hemophilia B, the disclosure said.
The pharmaceutical company obtained the approval for the trials after completing the Chinese drug administration's clinical ethics review and clinical pre-enrollment preparations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.